Corbett Elizabeth L, Marston Barbara, Churchyard Gavin J, De Cock Kevin M
London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
Lancet. 2006 Mar 18;367(9514):926-37. doi: 10.1016/S0140-6736(06)68383-9.
Rapid scale-up of antiretroviral treatment programmes is happening in Africa, driven by international advocacy and policy directives and supported by unprecedented donor funding and technical assistance. This welcome development offers hope to millions of HIV-infected Africans, among whom tuberculosis is the major cause of serious illness and death. Little in the way of HIV diagnosis or care was previously offered to patients with tuberculosis, by either national tuberculosis or AIDS control programmes, with tuberculosis services focused exclusively on diagnosis and treatment of rising numbers of patients. Tuberculosis control in Africa has yet to adapt to the new climate of antiretroviral availability. Many barriers exist, from drug interactions to historic differences in the way that tuberculosis and HIV are perceived, but failure to successfully integrate HIV and tuberculosis control will threaten the viability of both programmes. Here, we review tuberculosis epidemiology in Africa and policy implications of HIV/AIDS treatment scale-up.
在国际倡导和政策指令的推动下,同时获得前所未有的捐助资金和技术援助的支持,抗逆转录病毒治疗项目正在非洲迅速推广。这一令人欣喜的进展为数百万感染艾滋病毒的非洲人带来了希望,在这些人中,结核病是导致重病和死亡的主要原因。此前,国家结核病防治项目或艾滋病防治项目几乎都没有为结核病患者提供艾滋病毒诊断或护理服务,结核病服务仅专注于诊断和治疗越来越多的患者。非洲的结核病防治工作尚未适应抗逆转录病毒药物可及性的新环境。存在许多障碍,从药物相互作用到结核病和艾滋病毒认知方式上的历史差异,但未能成功整合艾滋病毒和结核病防治工作将威胁到这两个项目的可行性。在此,我们回顾非洲的结核病流行病学以及扩大艾滋病毒/艾滋病治疗规模的政策影响。